A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-12

Study Completion Date

2023-02-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this healthy volunteers drug-drug interaction study is to assess the CYP1A2 and CYP3A4 perpetrator interaction potential and CYP1A2 victim potential of TEV-56286 (anle138b).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AV650 Drug-Drug Interaction Study

NCT00456560

Healthy

COMPLETED PHASE1

Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects

NCT06232109

Drug Drug Interaction

COMPLETED PHASE1

Lofexidine Pharmacokinetics in the Presence of Paroxetine in Healthy Volunteers

NCT02681198

Healthy

COMPLETED PHASE1

Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

NCT00741468

Drug Interactions

COMPLETED PHASE1

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

NCT03827668

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This a 2-part DDI study that will assess the CYP1A2 and CYP3A4 perpetrator interaction potential of TEV-56286 single dose and multiple dose, using caffeine and midazolam as substrates and CYP1A2 victim potential of TEV-56286 (anle138b) at steady state induction using fluvoxamine as inhibitor \[1,2\].The estimated time from screening until the follow-up visit is approximately up to 8 weeks for each subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Drug drug interaction study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

anle138b (TEV-56286) as perpetrator (part I)

Drug: TEV-56286 300 mg QD (single dose and multiple dose for 14 days)

Victim drugs:

Caffeine 200 mg Midazolam 2 mg

Group Type EXPERIMENTAL

anle138b (TEV-56286)

Intervention Type DRUG

Anle138b (TEV-56286) as perpetrator

anle138b (TEV-56286) as victim (part II)

Drug: fluvoxamine 100 mg QD for 5 days

Victim drug:

TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine

Group Type EXPERIMENTAL

Fluvoxamine 100 mg QD for 5 days

Intervention Type DRUG

Anle138b (TEV-56286) as victim

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

anle138b (TEV-56286)

Anle138b (TEV-56286) as perpetrator

Intervention Type DRUG

Fluvoxamine 100 mg QD for 5 days

Anle138b (TEV-56286) as victim

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Caffeine Midazolam Fluvoxamine TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy males or healthy females of non-childbearing potential
* Must provide written informed consent for participation in the study and must be able to understand the study requirements
* Body mass index (BMI) 18.5 to 32.0 kg/m2.
* Must agree to adhere to the contraception requirements defined in the study protocol.

Exclusion Criteria

* Serious adverse reaction or serious hypersensitivity to any drug or formulation excipients e.g. fluvoxamine, caffeine, midazolam or benzodiazepines or any of its excipients, or a known drug hypersensitivity idiosyncratic reaction to TEV-56286, or one of its excipients
* History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, metabolic diseases or a history of any illness that, in the opinion of the investigator, might pose additional risk to the subject by participation in the study or confound the results of the study
* Acute infection and/or antibiotic treatment within 28 days of Day 1
* Major trauma or surgery in the 2 months before screening or at any time between screening and Day 1, or surgery scheduled during the study or follow up period
* History of malignancy or treatment of malignancy in the last 5 years
* History of suicidal ideation with an intent and/or plan and behaviour based upon either clinical history or source documents
* Personal or family history of arrhythmia, sudden unexplained death at a young age (before 40 years) in a first-degree relative, or long QT syndrome, or a personal history of syncope or previous treatment for high blood pressure (BP). Abnormality of 12-lead ECG that may, in the opinion of the investigator, interfere with study participation
* Any procedure or disorder that may interfere with drug absorption, distribution, metabolism, or excretion
* Clinically significant abnormal clinical chemistry, haematology or urinalysis as judged by the investigator.
* Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer
* Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies in the 14 days before study medication administration or within 5 half-lives whichever is longer.
* Subjects who are taking, or have taken hormonal contraceptives (e.g., oral, patch, injectable or intrauterine device) hormone replacement therapy (HRT) or a long-acting injectable hormonal within 4 weeks prior to first dose of IMP
* Subjects who are taking, or have taken any inducer of CYP 1A2, CYP3A4 within 28 days prior to Day -2
* History of any drug or alcohol abuse in the past 2 years
* Current smokers and those who have smoked within the last 12 months or has a positive urine cotinine test
* Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
* Subjects with a previous history of difficulty in swallowing tablets or capsules, or an anticipated problem with swallowing a large number of capsules
* Subjects who have consumed grapefruit, grapefruit juice, Seville oranges, pomelo-containing products, vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, brussel sprouts, and mustard) and charbroiled meats within the 14 days prior to Day -2
* Subjects who are unwilling to comply with the restricted use of caffeinated beverages (e.g. coffee, tea, cola) during the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes